Gastrointestinal system involvement is a rare presentation of Multiple Myeloma (MM) and is associated with poor prognosis and short-lasting remissions despite aggressive treatment. We present a patient with asymptomatic elevation of liver tests, found to have multiple myeloma involvement of the liver.

Another caution: while drinking does not seem associated with risk of developing multiple myeloma, it is statistically associated with increased risk of developing breast cancer, esophageal cancers and others.

In general, liver involvement in myeloma is a rare event. However, direct infiltration of the liver leading to intrahepatic cholestasis, or involvement of large bile ducts leading to obstructive jaundice, has still been described.

Diffuse hepatic infiltration occurs in more than 50% of cases with multiple myeloma, especially at the end stage. 1 Liver involvement by multiple myeloma as space-occupying lesions is a very rare condition, that mimics metastatic tumours on imaging techniques.

The overall range of life expectancy in multiple myeloma patients extends from 1 year to more than 10 years in some cases. The median life expectancy in general is 3 years. Statistics reveal that about 35% or one third of affected patients live for five years.

Multiple myeloma used to be considered extremely deadly; today many people live with it as little more than a chronic condition. One reason it remains deadly is because many patients can’t get optimal therapy as a consequence of having existing illnesses when diagnosed with cancer.

Signs and symptoms of multiple myeloma can vary and, early in the disease, there may be none. When signs and symptoms do occur, they can include: Bone pain, especially in your spine or chest. Nausea. Constipation.

There is no cure for multiple myeloma, but the disease can be managed by appropriate treatment. Various supplements such as herbal and vitamins and minerals help improve the condition of patients.